While it's far too early to begin talking about a phoenix-like resurgence, Johnson & Johnson shows initial signs of at least shaking up what in recent years has become a far too comfortably stratified coronary stent market. This after J&J's Cordis Corp. received FDA approval of its new Bx Velocity stent in mid-May, several weeks earlier than anticipated.
It used to be that the stent market could be relied on to periodically produce dramatic Nasdaq-like shifts in market...